<drug type="biotech" created="2016-06-24" updated="2016-08-17">
  <drugbank-id primary="true">DB11608</drugbank-id>
  <name>Eftrenonacog alfa</name>
  <description/>
  <cas-number>1270012-74-2</cas-number>
  <unii>02E00T2QDE</unii>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
  </general-references>
  <synthesis-reference/>
  <indication/>
  <pharmacodynamics/>
  <mechanism-of-action/>
  <toxicity/>
  <metabolism/>
  <absorption/>
  <half-life/>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="" coder="">Coagulation factor IX recombinant immunoglubulin g1 fusion protein</synonym>
    <synonym language="" coder="">Recombinant human coagulation factor IX, FC Fusion protein</synonym>
  </synonyms>
  <products>
    <product>
      <name>Alprolix</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02422905</dpd-id>
      <started-marketing-on/>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>250 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alprolix</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02422921</dpd-id>
      <started-marketing-on>2016-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>1000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alprolix</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02422956</dpd-id>
      <started-marketing-on>2016-01-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>3000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alprolix</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02422913</dpd-id>
      <started-marketing-on>2015-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>500 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Alprolix</name>
      <labeller>Biogen</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>02422948</dpd-id>
      <started-marketing-on>2015-12-11</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Kit; Powder, for solution</dosage-form>
      <strength>2000 unit</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Alprolix</name>
      <ingredients>Eftrenonacog alfa</ingredients>
    </mixture>
    <mixture>
      <name>Alprolix</name>
      <ingredients>Eftrenonacog alfa</ingredients>
    </mixture>
    <mixture>
      <name>Alprolix</name>
      <ingredients>Eftrenonacog alfa</ingredients>
    </mixture>
    <mixture>
      <name>Alprolix</name>
      <ingredients>Eftrenonacog alfa</ingredients>
    </mixture>
    <mixture>
      <name>Alprolix</name>
      <ingredients>Eftrenonacog alfa</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories/>
  <affected-organisms/>
  <dosages>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>1000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>2000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>250 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>3000 unit</strength>
    </dosage>
    <dosage>
      <form>Kit; powder, for solution</form>
      <route>Intravenous</route>
      <strength>500 unit</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>22263</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>
